In a report released on January 27, Naz Rahman from Maxim Group reiterated a Buy rating on Silexion Therapeutics (SLXN – Research Report), with a price target of $9.00. The company’s shares ...

Silexion Therapeutics Corp. (SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today ...

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages ...

What is the current share price of Silexion Therapeutics Corp (SLXN)? Silexion Therapeutics Corp's (SLXN) current share price is $1.08. This constitutes a price movement of 14.29% when compared to the ...

Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for ...

It expects to announce details of its expanded development plan shortly. Price Action: SLXN stock is up 130.2% at $1.33 at last check Tuesday.

Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech ...

Silexion Therapeutics (SLXN) announced new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. The findings contribute to validating systemic administration as an ...

On Tuesday, Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. SIL-204, administered in an extended-release ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

(RTTNews) - Silexion Therapeutics Corp. (SLXN), a clinical-stage biotechnology company, announced Tuesday significant preclinical data for SIL-204, its next-generation siRNA therapeutic candidate ...

On Tuesday, Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. SIL-204, administered in an extended-release ...